Beach Investment Counsel Inc. PA Sells 450 Shares of Stryker Co. (NYSE:SYK)

Beach Investment Counsel Inc. PA reduced its position in Stryker Co. (NYSE:SYK) by 33.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 900 shares of the medical technology company’s stock after selling 450 shares during the period. Beach Investment Counsel Inc. PA’s holdings in Stryker were worth $324,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Czech National Bank lifted its holdings in Stryker by 8.1% in the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after buying an additional 5,235 shares during the period. GAMMA Investing LLC boosted its holdings in Stryker by 38.7% during the third quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock worth $1,048,000 after buying an additional 810 shares during the last quarter. Diversified Trust Co grew its position in shares of Stryker by 5.8% during the 3rd quarter. Diversified Trust Co now owns 14,581 shares of the medical technology company’s stock worth $5,268,000 after buying an additional 800 shares during the period. Consilio Wealth Advisors LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $210,000. Finally, Miracle Mile Advisors LLC raised its position in shares of Stryker by 569.2% in the 3rd quarter. Miracle Mile Advisors LLC now owns 5,983 shares of the medical technology company’s stock valued at $2,161,000 after acquiring an additional 5,089 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

Stryker Stock Down 0.3 %

Stryker stock opened at $389.94 on Tuesday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The stock has a market cap of $148.65 billion, a P/E ratio of 50.26, a P/E/G ratio of 2.78 and a beta of 0.96. The company’s 50-day moving average price is $376.68 and its two-hundred day moving average price is $363.22. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business posted $3.46 EPS. As a group, analysts expect that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were paid a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Tuesday, December 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.